Mario Gabelli's LLY Position Overview
Mario Gabelli (via Gamco Investors, Inc. Et Al) currently holds 24,876 shares of Eli Lilly and Company (LLY) worth $26.73 M, representing 0.26% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Mario Gabelli has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2022, adding 11,759 shares. Largest reduction occurred in Q4 2017, reducing 21,750 shares.
Analysis based on 13F filings available since 2013 Q2
Mario Gabelli's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Mario Gabelli
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -106 | Reduce 0.42% | 24,876 | $1074.68 |
| Q3 2025 | -2,417 | Reduce 8.82% | 24,982 | $763.00 |
| Q2 2025 | -2,671 | Reduce 8.88% | 27,399 | $779.53 |
| Q1 2025 | -3,473 | Reduce 10.35% | 30,070 | $825.91 |
| Q4 2024 | -1,269 | Reduce 3.65% | 33,543 | $772.00 |
| Q3 2024 | -1,017 | Reduce 2.84% | 34,812 | $885.94 |
| Q2 2024 | -520 | Reduce 1.43% | 35,829 | $905.38 |
| Q1 2024 | -286 | Reduce 0.78% | 36,349 | $777.96 |
| Q4 2023 | +6,054 | Add 19.80% | 36,635 | $582.92 |
| Q3 2023 | -893 | Reduce 2.84% | 30,581 | $537.13 |
| Q2 2023 | +941 | Add 3.08% | 31,474 | $468.98 |
| Q1 2023 | -322 | Reduce 1.04% | 30,533 | $343.42 |
| Q4 2022 | +11,759 | Add 61.58% | 30,855 | $365.84 |
| Q3 2022 | +726 | Add 3.95% | 19,096 | $323.37 |
| Q2 2022 | -545 | Reduce 2.88% | 18,370 | $324.22 |
| Q1 2022 | -225 | Reduce 1.18% | 18,915 | $286.39 |
| Q4 2021 | -125 | Reduce 0.65% | 19,140 | $276.23 |
| Q3 2021 | -714 | Reduce 3.57% | 19,265 | $231.04 |
| Q2 2021 | -1,216 | Reduce 5.74% | 19,979 | $229.54 |
| Q1 2021 | +83 | Add 0.39% | 21,195 | $186.84 |
| Q4 2020 | -1,392 | Reduce 6.19% | 21,112 | $168.86 |
| Q3 2020 | +192 | Add 0.86% | 22,504 | $148.02 |
| Q2 2020 | -5,400 | Reduce 19.49% | 22,312 | $164.17 |
| Q1 2020 | -1,900 | Reduce 6.42% | 27,712 | $138.71 |
| Q4 2019 | -3,625 | Reduce 10.91% | 29,612 | $131.43 |
| Q3 2019 | -1,200 | Reduce 3.48% | 33,237 | $111.83 |
| Q2 2019 | +9,300 | Add 37.00% | 34,437 | $110.78 |
| Q1 2019 | -11,103 | Reduce 30.64% | 25,137 | $129.77 |
| Q4 2018 | -4,525 | Reduce 11.10% | 36,240 | $115.73 |
| Q3 2018 | -8,550 | Reduce 17.34% | 40,765 | $107.30 |
| Q2 2018 | -1,635 | Reduce 3.21% | 49,315 | $85.33 |
| Q1 2018 | -1,150 | Reduce 2.21% | 50,950 | $77.37 |
| Q4 2017 | -21,750 | Reduce 29.45% | 52,100 | $84.45 |
| Q3 2017 | -2,950 | Reduce 3.84% | 73,850 | $85.54 |
| Q2 2017 | -2,300 | Reduce 2.91% | 76,800 | $82.30 |
| Q1 2017 | -1,450 | Reduce 1.80% | 79,100 | $84.11 |
| Q4 2016 | -1,500 | Reduce 1.83% | 80,550 | $73.54 |
| Q3 2016 | -700 | Reduce 0.85% | 82,050 | $80.26 |
| Q2 2016 | -1,200 | Reduce 1.43% | 82,750 | $78.76 |
| Q1 2016 | -400 | Reduce 0.47% | 83,950 | $72.01 |
| Q4 2015 | -13,550 | Reduce 13.84% | 84,350 | $84.26 |
| Q2 2015 | -13,900 | Reduce 12.43% | 97,900 | $83.49 |
| Q1 2015 | -2,000 | Reduce 1.76% | 111,800 | $72.65 |
| Q4 2014 | -800 | Reduce 0.70% | 113,800 | $68.99 |
| Q3 2014 | -5,400 | Reduce 4.50% | 114,600 | $64.85 |
| Q2 2014 | -900 | Reduce 0.74% | 120,000 | $62.17 |
| Q1 2014 | -3,000 | Reduce 2.42% | 120,900 | $58.86 |
| Q4 2013 | -600 | Reduce 0.48% | 123,900 | $51.00 |
| Q3 2013 | -2,500 | Reduce 1.97% | 124,500 | $50.33 |
| Q2 2013 | +127,000 | Add 0.00% | 127,000 | $49.12 |
Mario Gabelli's Eli Lilly and Company Investment FAQs
Mario Gabelli first purchased Eli Lilly and Company (LLY) in Q2 2013, acquiring 127,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mario Gabelli has held Eli Lilly and Company (LLY) for 51 quarters since Q2 2013.
Mario Gabelli's largest addition to Eli Lilly and Company (LLY) was in Q2 2013, adding 127,000 shares worth $6.24 M.
According to the latest 13F filing for Q4 2025, Mario Gabelli's firm, Gamco Investors, Inc. Et Al, owns 24,876 shares of Eli Lilly and Company (LLY), valued at approximately $26.73 M.
As of the Q4 2025 filing, Eli Lilly and Company (LLY) represents approximately 0.26% of Mario Gabelli's publicly disclosed stock portfolio, making it one of their key holdings.
Mario Gabelli's peak holding in Eli Lilly and Company (LLY) was 127,000 shares, as reported at the end of Q2 2013.